PORCINE TESCHOVIRUS (PTV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Not feasible: Eradication extremely unlikely
OVERVIEW
Porcine teschoviruses (PTVs) are ubiquitous picornaviruses that infect pigs worldwide. The first evidence of PTV infection was Teschen disease, a severe polioencephalomyelitis with high mortality described in Czechoslovakia over 75 years ago. Today it is recognized that no conventional pig herd has been demonstrated to be free of PTV infection—the viruses are endemic in virtually all pig populations. While the majority of PTV infections are subclinical, the viruses have been associated with a variety of clinical conditions including polioencephalomyelitis, reproductive disease (SMEDI syndrome: Stillbirth, Mummified fetuses, Embryonic Death, Infertility), enteric disease, pneumonia, pericarditis, and myocarditis. Currently, 19 types are recognized within species Teschovirus A (PTV-1 through PTV-19), plus three additional types in species Teschovirus B. The virulent PTV-1 strains that cause classical Teschen disease appear restricted to Central Europe and parts of Africa—they have not been isolated in North America. Less virulent PTV-1 strains causing milder disease (Talfan disease, benign enzootic paresis) and other PTV types are distributed globally. Teschen disease (teschovirus encephalomyelitis) remains a WOAH-notifiable disease. Endemic infection with multiple PTV serotypes is typical in conventional herds, maintained primarily in groups of weaned piglets. Piglets normally acquire infection shortly after weaning when maternal antibodies decline and pigs from multiple litters are mixed. PTVs are highly resistant to environmental inactivation and many disinfectants.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter explicitly states: "PTVs are not infectious for humans." Despite ubiquitous infection in pig populations worldwide and extensive human exposure through farming, slaughter, and consumption of pork products, no human PTV infections have been documented. The virus poses no foodborne risk.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
PTVs do not infect humans. No occupational infections have been documented among farm workers, veterinarians, or laboratory personnel despite the universal presence of these viruses in pig populations.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
PTV transmission occurs primarily by the fecal-oral route, with indirect transmission via fomites possible due to the virus's environmental stability. The chapter describes the typical epidemiology: "Endemic infection with several PTV serotypes can usually be demonstrated in conventional herds and is probably maintained in groups of weaned piglets." Infection occurs "shortly after weaning, when maternally derived antibodies decline and pigs from several litters are mixed, and it persists for at least several weeks." Adults rarely excrete virus but maintain high antibody levels. Critically, "pigs of any age are fully susceptible to infection with a virus belonging to a serotype/genotype to which they have not previously been exposed"—meaning introduction of new serotypes through replacement animals or contaminated fomites remains a risk. Standard biosecurity (controlling animal introductions, cleaning and disinfection, all-in/all-out management) can prevent introduction of virulent strains not already present. However, eliminating endemic PTV circulation is essentially impossible given the virus's ubiquity and resistance to inactivation. The chapter notes that "exclusion of PTVs by repopulation of herds with specific pathogen-free (SPF) stock seems difficult or impossible to achieve over a prolonged period."
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical diagnosis is challenging because most PTV infections are subclinical, and when clinical signs occur, they are not pathognomonic. Neurological signs (polioencephalomyelitis) are suggestive of viral etiology but require differentiation from other neurotropic viruses. Reproductive disorders (SMEDI) overlap with parvovirus and other pathogens. Teschen disease is described as "a disease of high morbidity and high mortality, affecting all ages of swine"—the more severe presentation may be clinically recognized, while milder Talfan disease may be missed. Laboratory confirmation is straightforward: PTVs grow readily in porcine kidney cells (primary, secondary, or cell lines like IB-RS-2); identified by virus neutralization, complement fixation, or immunofluorescence with reference reagents; and RT-PCR assays (including real-time methods) are available for detection and differentiation. Virus isolation from CNS requires early sampling—"animals that have been paralyzed for several days may no longer harbor infectious virus in the CNS." Isolation from intestine is common but not diagnostic since enteric infections are ubiquitous even in healthy pigs. Teschen disease is WOAH-notifiable with internationally accepted diagnostic methods described in the WOAH Manual.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
The economic impact of PTV infection varies dramatically depending on the strain and serotype involved: (1) Teschen disease (virulent PTV-1): "a disease of high morbidity and high mortality, affecting all ages of swine and associated with major economic losses"—clinical signs include fever, anorexia, progressive paralysis, convulsions, and coma with death within 3-4 days; (2) Talfan disease (less virulent strains): "milder disease with relatively low morbidity and mortality," mainly affecting young pigs; (3) SMEDI syndrome: reproductive losses including mummified fetuses, stillbirths, embryonic death, and infertility—economically important but shared with other pathogens (especially parvovirus); (4) Most infections: subclinical with no production impact. The virulent PTV-1 strains causing Teschen disease "appear to be restricted to those areas in which the disease occurs, and they have not been isolated in North America." Endemic PTV infection in most pig populations causes minimal ongoing losses because most circulating strains are of low virulence and pigs develop immunity through natural exposure. Economic impact is primarily associated with introduction of virulent strains into naive populations or SMEDI-associated reproductive losses.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
Teschen disease (teschovirus encephalomyelitis) is WOAH-notifiable, meaning detection of virulent PTV-1 would trigger regulatory response. However: (1) the virulent strains are geographically restricted and have never been detected in North America; (2) endemic circulation of non-virulent PTVs is universal and expected—it does not affect trade status; (3) PTV infection is not itself a basis for trade restrictions since essentially all pig populations are infected. Market impacts would only occur if virulent Teschen disease strains were detected in a previously unaffected country. "Restrictions on the import of swine and pork products from areas in which Teschen disease is endemic seem to be effective in limiting the spread of virulent PTV-1 strains."
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PTVs are viral pathogens (positive-sense single-stranded RNA picornaviruses) that do not carry, acquire, or transmit antimicrobial resistance genes. The viruses pose no AMR concerns. Multiple serotypes and genetic diversity exist (19 types in Teschovirus A, 3 in Teschovirus B), representing viral evolution and diversity rather than antimicrobial resistance. Cross-protection between serotypes may be limited, meaning immunity to one type does not necessarily protect against others.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PTV infections. The chapter notes that "potential antiviral chemotherapeutics for porcine enteric picornaviruses have received little attention." Management relies on: prevention of introduction of virulent strains through biosecurity; ensuring gilts are exposed to endemic strains before breeding (for SMEDI prevention); and supportive nursing care for pigs with mild paralysis. Antimicrobials are not used routinely for PTV prevention or treatment. Any antimicrobial use would be for secondary bacterial complications, representing rare individual animal treatment.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments exist for PTV infection. "Piglets with mild polioencephalomyelitis may recover if nursing care is provided during the period of transient paresis"—this is supportive care only, not treatment of viral infection. For severe Teschen disease, most affected animals die despite care. For SMEDI syndrome, fetal damage cannot be reversed once it occurs. No antiviral drugs are available for PTVs.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Vaccines have been developed and used for control of Teschen disease: "The earlier Teschen disease vaccines containing inactivated virus of pig tissue origin have been superseded by attenuated or inactivated cell culture vaccines." Live-attenuated and formalin-inactivated vaccines "induced similar levels of protection in piglets." Ring vaccination combined with slaughter was used successfully for Teschen disease eradication programs. However, vaccines are not widely used because: (1) Teschen disease is geographically restricted and rare; (2) endemic PTV strains are mostly non-pathogenic; (3) the multiplicity of serotypes complicates vaccine development—"the relatively large number of serotypes would suggest that cross-protection might not occur." For SMEDI prevention, "no vaccine has been produced, primarily because of the multiplicity of serotypes that may be involved." The practical approach for SMEDI prevention is management: exposing gilts to endemic viruses "at least 1 month before breeding" through natural exposure or feedback programs.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
PTV eradication from the US pig population is not feasible because: (1) Universal distribution: "no conventional pig herd has been shown to be free of infection"—PTVs are endemic in essentially all pig populations globally; (2) Environmental stability: PTVs "are highly resistant to inactivation in the environment and may survive for long periods in liquid manure"; (3) Disinfectant resistance: only sodium hypochlorite was effective among 10 commonly used disinfectants tested; (4) Multiple serotypes: endemic infection involves multiple serotypes that would all need to be eliminated; (5) Fomite transmission: the resistant viruses can spread via contaminated equipment, vehicles, and personnel; (6) SPF failure: "exclusion of PTVs by repopulation of herds with specific pathogen-free (SPF) stock seems difficult or impossible to achieve over a prolonged period"—even gnotobiotic pigs may be infected via transplacental transmission. The practical approach is preventing introduction of virulent Teschen disease strains (which have not been detected in North America) while accepting that endemic circulation of non-pathogenic PTVs is unavoidable.